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Study objectives: To determine the medications prescribed to patients with chronic
obstructive pulmonary disease (COPD) and their relationship to health-related
quality of life (HRQL).
Methods: Cross-sectional study of 611 consecutive patients with stable, mild-to-
severe COPD who attended at the respiratory service of a single hospital during a 1-
year period. HRQL was evaluated using the St. George Respiratory Questionnaire
(SGRQ) and the Short Form 36-item (SF-36) questionnaires. Linear regression analysis
was used to determine the influence of the number or type of medication on the
total SGRQ score, adjusting by disease severity and other relevant variables.
Results: Significant differences were observed among the number of drugs
prescribed according to dyspnea levels, percentage of predicted FEV1 (FEV1%),
SGRQ scores and some areas of SF-36. Fifty-nine percent of patients with
an FEV1%450% were prescribed inhaled corticosteroids (ICS). Those who took
an ICS had a worse HRQL than patients with an FEV1%450% who did not receive
ICS.
Conclusions: A relationship exists between the number of medicines prescribed to
patients with COPD and their HRQL, measured by the total SGRQ score, after
adjustment by severity of the disease. Within the group of patients who should not
have been prescribed ICS, there are subgroups that might benefit from this
medication.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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Clinical guidelines for treating stable chronic
obstructive pulmonary disease (COPD) from theed.
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C. Esteban et al.488American Thoracic Society (ATS) recommend a
scaled treatment from b2-adrenergics (b2A) on
demand to oral steroids (OCS) in accordance with
the patient’s symptoms.1 Other guidelines2,3 pro-
posed a scaled treatment in accordance with the
severity of the COPD and the patient’s symptoms.
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD)4 recommends the use of broncho-
dilator drugs in accordance with availability and
the extent to which these relieve the symptoms.
This guideline classifies severity in accordance with
forced expiratory volume in 1 s (FEV1), regardless of
the presence of symptoms. Thus, a short-acting b2A
would be prescribed when needed, giving way to
the possibility of using one or several bronchodila-
tors in moderate and severe COPD. With respect to
inhaled corticosteroids (ICS), although it is well-
known that these do not modify the progressive
decrease in FEV1,
5 these would be prescribed in the
case of symptomatic patients with spirometric
response to ICS or in patients with an percentage
of predicted FEV1 (FEV1%) o50% and with frequent
exacerbations.4
In spite of evidence-based guidelines regarding
the medical treatment of COPD, many clinicians
act at a consensus level rather than in accordance
with the evidence.6 Although few studies have
focused on the prescription of different drugs
available for COPD, the data show substantial
between-country differences in drugs prescribed
for COPD.7 Differences have even been observed
between primary health care and hospital care
within the same country.8,9 Moreover, the recom-
mendations set out in guidelines for treating
COPD are often disregarded. In fact, some
studies show that the use of methylxanthines still
exceeds that of anticholinergics (AC) even when
guidelines relegate the prescription of methyl-
xanthines to a secondary level, after AC and
b2A.
10 The extensive use of ICS (probably
above the figures that would normally be expected
if the indications contained in the guidelines were
strictly adhered to), should be highlighted in this
regard.11
Taking into consideration the differences de-
scribed above, there has been a change in the
pattern of prescribing medications to treat COPD,
consisting of an increase in the use of b2A, AC, and
ICS, along with a decrease in the use of methyl-
xanthines.12,13
The aim of this study was to determine
what medications are prescribed for patients with
COPD, with special emphasis on ICS and the
relationship between the number of medicines
prescribed and health-related quality of life
(HRQL).Methods
For a period of one year, from February 1998 to
February 1999, we recruited all patients under age
81 who had been previously diagnosed with COPD
and who came to one of five out-patient clinics
affiliated with a single hospital. The catchment
area of the hospital has a population of 300,000
distributed among urban and rural centers.
Patients were included in the study consecutively
and, in order to be included, had to have been
diagnosed or monitored for their COPD by one of
the clinics for at least 6 months prior to the study.
Moreover, a stable clinical status (no increase in
respiratory symptoms or modifications in the
treatment) over the previous 6 weeks was required.
The two criteria for including patients in the
study were as follows: (1) FEV1o80% of a theore-
tical reference with an FEV1/FVCo70%. (2) Nega-
tive bronchodilation test with an FEV1 increase
o200ml and 15% with respect to the basal value.
Patients older than age 80 and those diagnosed with
asthma, extensive residual pulmonary tuberculosis,
malignant neoplastic processes, psychiatric or
neurological diseases that prevented an adequate
level of collaboration, as well as deafness (if this
prevented adequate communication), were ex-
cluded from the study. Patients age 480 were
excluded due to the difficulty that patients in this
age group would have had in completing the
questionnaires and undergoing the spirometry test.
All patients were asked for their authorization in
order to include them in the study.
During this 1-year period, 739 consecutive
patients were identified as having COPD, of whom
128 were excluded. Reasons for exclusion were as
follows: 63 patients were over 80 years of age
(49%), 31 with neoplasia (24%), 11 with severe
hypoacusia (9%), 10 with dementia (8%), 4 who
could not perform spirometry (3%), and 9 for a
variety of other reasons (7%). The remaining
patients agreed to participate.
Prior to the start of the study, patients had been
instructed periodically on basic aspects of their
illness such as the need to stop smoking and the
advisability of doing physical exercise, consisting
basically of walking everyday, and had been trained
in the use of inhalation devices.
The entire assessment was carried out on a single
day. The patients answered a general questionnaire
on aspects such as their socio-demographic vari-
ables, the use of medication with regard to their
bronchial disorder, associated diseases, previous
hospitalizations and general health status. They
were questioned with regard to their level of
dyspnea using a 5-degree scale adapted from
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intense and strenuous exercise,’’ degree II ‘‘cap-
able of walking at the same pace as other people of
my age on the level,’’ degree III ‘‘capable of
walking on the level at my own speed without
dyspnea, but incapable of walking at the same pace
as persons of my own age,’’ degree IV ‘‘dyspnea
after walking slowly for 100 meters,’’ and degree V
‘‘dyspnea when resting or after slight effort such as
getting dressed.’’
Spirometry was performed according to the
regulations of the ATS and the Sociedad Espan˜ola
de Patologı´a del Aparato Respiratorio (SEPAR)15
with a Master-Scope-PC spirometer (Erich Jaeger
GmbH & Co, KG, Wuerburg, Germany). The
theoretical values were those referenced by
the European Community for Steel and Coal.16
The severity of the COPD was defined according to
GOLD stages system.4
Health-related quality of life was assessed
according to the Short Form 36-item (SF-36) and
the St. George Respiratory Questionnaire (SGRQ).
The SF-36 is a generic quality-of-life questionnaire
relating to health and consists of 36 items covering
eight dimensions (areas): physical function, role
physical, bodily pain, general health, vitality, social
function, role emotional and mental health. Each
area scores from 0 to 100, 100 being the best
possible score and therefore the best state of
health. The validated Spanish version of the SF-36
was used.17
The SGRQ is a specific quality-of-life question-
naire consisting of 50 questions distributed in three
areas: symptoms, impact, and activity. Each area
scores from 0 to 100, 0 indicating an absence of
deterioration. There is also a total score which is
calculated by using a weighting factor for each
question in the questionnaire18 and which ranges
between 0 and 100. The validated Spanish version
was used.19
Sociodemographic data, and other CLINICAL
variables were included in the database (as number
of assessments during the 2 previous years in
hospital emergency services or previous hospitali-
zations).
The interviewer was trained and limited himself
to reading the questionnaire without interpreting
the questions in any way.Statistical analysis
Means and standard deviations are presented for
continuous variables, and frequencies and percen-
tages for categorical variables. In order to study
the association between the number of drugs ortype of medicines with categorical variables, the
Chi-squared and the Fisher’s exact tests were
used. In order to study the association between
the number of drugs or type of medicines with
continuous variables, the ANOVA test and Scheffe
test were used for multiple comparisons. In the
latter case, the nonparametric Kruskal–Wallis test
was also used.
In addition, we studied the relationship between
the number of medicines prescribed and the total
SGRQ score, adjusted for other relevant variables.
In this case, two linear regression models were used
in which the dependent variable was the total
SGRQ score. In the first model, the relationship of
the independent variable number of medicines was
studied. In the second model, also with the number
of medicines as independent variable, a differen-
tiation was made between those who took ICS as
the second prescribed medicine and those who did
not. In both models, the comparison group was
composed of patients who did not take any
medications. Both models were adjusted for vari-
ables such as age, FEV1, dyspnea, comorbidities and
the number of previous hospitalizations.
All effects are significant at Po0:05 unless
otherwise noted. Data was entered with Epi Info
version 6.4 and all statistical analyses were
performed using SAS for Windows statistical soft-
ware, version 8.02 (SAS, Cary, NC, USA).Results
A total of 611 patients took part in this study. The
average age of the patients was 67.2 years, and
97.7% were male. Smoking was common, with
21.3% reporting they were current smokers and
96.6% reporting a current or previous history of
smoking. The average number of packs/year was
49.4. Of all patients, only 93 (15.22%) did not have
any relevant comorbidity. The mean FEV1 was
1.37 L (SD ¼ 1.46) and the FEV1 with respect to the
predicted value (FEV1%) was 49.7% (SD ¼ 14.56).
During the 2 previous years, 36% of patients had
been admitted to hospital at least once (Table 1).
According to the GOLD classification 304 (49.7%)
were in stage II, 267 (43.7%) in stage III and 40
(6.6%) in the IV (Table 1). No patients were on stage
0 or I.
With regard to medication use for COPD
(Table 2), 93% used b2A, 86.4% used AC, and
66.1% received ICS. Among patients who used a
single drug, in most cases these were b2A (56%)
and, to a lesser extent, AC (40%). ICS represented
the third most frequently used drug, although it
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medicines and by 100% of those who required four
drugs. The most widely used combination (49% of
patients) included three medications—b2A, AC, and
ICS. Methylxanthines were used specifically in
patients requiring four medicines to treat theirTable 1 Characteristics of the COPD study sam-
ple ðn ¼ 611Þ.
Age, yr (mean, SE) 67.2 8.4
Men 597 97.7
Smoking-habit
Active smokers 130 21.3
Ex smokers 460 75.3
No smokers 21 3.4
Pack-years (mean, SE) 47.7 28.7
FEV1 L (mean, SE) 1.37 0.46
FEV1% (mean; SE) 49.7 14.56
FEV1/VC (mean, SE) 50 10.32
GOLD stages
II (number, %) 304 49.7
III (number, %) 267 43.7
IV (number, %) 40 6.6
Main comorbidities
Hypertension 171 28
Diabetes 106 17.3
Heart problems 149 24.4
Back disorders 225 36.8
Osteoarthritis/rheumatism 265 43.4
Psychiatric problems 78 12.8
Dyspnea categoriesa
I 44 7.2
II 306 50.1
III 233 38.1
XIV 28 4.6
FEV1%: % FEV1 of predicted value.
All the variables in frequencies and percentages except
where are indicated.
aAccording to Fletcher et al. [14].
Table 2 Type of drugs recommended according to the n
Number of medications Type of medication
b2A AC
1 14 (56) 10 (40)
2 179 (96.8) 146 (78.9)
3 302 (100) 299 (99)
X4 73 (100) 73 (100)
Total 568 (93) 528 (86.4)
b2A: b2-agonists; AC: anticholinergics; ICS: inhaled corticosteroid
Frequency and, in brackets, percentages.illness. OCS were the least commonly used. Only 26
patients did not receive any kind of regular
medication. None of the patients used oral b2A.
Classifying patients in accordance with the
number of medicines used to treat their COPD
(Table 3) revealed a significant decrease in FEV1%
ðPo0:001Þ as the number of medications increased.
Dyspnea and FEV1%, categorized according to the
GOLD classification of severity also showed signifi-
cant differences with respect to the use of drugs
ðPo0:001Þ,with a larger number of drugs prescribed
among those with a lower FEV1% or higher dyspnea.
With regard to HRQL, as the number of medicines
used increased, all areas of the SGRQ reflected a
poorer quality of life. The SF-36 showed greater
deterioration in the areas of physical functioning
(PF), role physical, general health, and vitality,
although no significant differences were found in
other areas.
ICS are the third most common drug chosen in the
treatment of patients with COPD. By analyzing
patients with an FEV1% 450%, we found that 181
(59%) used ICS. Comparing the characteristics of
these patients, we found no statistically significant
differences by age or by FEV1% with respect to
patients with an FEV1 450% who did not take ICS
(Table 4). Nevertheless, there were significant
differences with regard to the number of assess-
ments during the 2 previous years in hospital
emergency services, with a higher frequency of
assessments among those treated with ICS. Among
patients who received ICS, SF-36 scores were
significantly worse only in PF ðPo0:003Þ compared
with those who had not been prescribed ICS. In the
SGRQ, those patients who took ICS had a worse
quality of life in all areas, showing statistically
significant differences and exceeding in all cases
the four points of difference between both groups.
Among patients who used two medications, the
majority used two bronchodilators. In the case of
42 patients, ICS were prescribed in preference to
another bronchodilator (Table 3). These patientsumber of drugs used.
ICS Theo OCS Total
0 (0) 1 (4) 0 (0) 25 (4.27)
42 (22.7) 3 (1.62) 0 (0) 185 (31.62)
289 (95.7) 15 (4.97) 1 (0.33) 302 (51.62)
73 (100) 68 (93.1) 14 (19.2) 73 (12.48)
404 (66.1) 87 (14.2) 15 (2.4)
s; Theo: theophyllines; OCS: oral corticosteroids.
ARTICLE IN PRESS
Table 3 Patients characteristics according to number of medications.a
Number of drugs P-value
0 1 2(ICS) 2 (no ICS) 3 X4
(26) (25) (143) (42) (302) (73)
Age, yr, mean7SD 63.3 (9.0) 64.3 (9.3) 63.3 (10.0) 66.8 (8.2) 67 (8.3) 69.2 (6.6) 0.001
Pack-years mean7SD 51.1 (28) 48.7 (23.9) 44.0 (26.3) 52.2 (31.4) 46.6 (28.3) 44.4 (27.4) 0.30
FEV1% 59.5 (10.2) 57.2 (15.1) 58.3 (14.4) 50.4 (13.2) 49.5 (14.4) 38.4 (11.3) o0.001
GOLD stages o0.001
II 23 (7.6) 18 (5.9) 79 (26) 27 (8.9) 147 (48.4) 10 (3.3)
III 3 (1.1) 5 (1.9) 58 (21.7) 15 (5.6) 136 (50.9) 50 (18.7)
IV 0 2 (5) 6 (15) 0 19 (47.5) 13 (32.5)
Dyspnea categories o0.001
Grade I 9 (34.6) 5 (20) 8 (19.1) 9 (6.3) 13 (4.3) 0 (0)
Grade II 14 (53.9) 14 (56) 23 (54.8) 87 (60.8) 145 (48) 23 (31.5)
Grade III 3 (11.5) 5 (20) 11 (26.2) 41 (28.7) 133 (44) 40 (54.8)
Grade IV–V 0 (0) 1 (4) 0 (0) 6 (4.2) 11 (3.6) 10 (13.7)
Previous hospitalizations o0.001
None 24(92.3) 21 (84.0) 33 (78.6) 78 (54.6) 198 (65.5) 33 (45.2)
1 2 (7.7) 3 (12.0) 5 (11.9) 42 (29.4) 59 (19.5) 20 (27.4)
X2 0 (0) 1 (4.0) 4 (9.1) 23 (16.1) 45 (14.5) 20 (27.4)
SF-36
Physical functioning 80.6 (13) 70.4 (22.1) 65.4 (24.7) 65.3 (22.9) 58.5 (21.8) 50.7 (23.9) o0.001
Role physical 89.4 (28.4) 72.0 (41.0) 83.9 (34.0) 80.6 (33.9) 75.7 (36.0) 66.8 (41.7) 0.026
Bodily pain 73.0 (25.5) 68.2 (30.2) 64.6 (26.9) 73.3 (26.6) 71.2 (28.7) 73.1 (25.6) 0.56
General health 57.1 (22.5) 50.0 (19.9) 55.5 (24.5) 50.3 (20.3) 43.7 (22.0) 38.5 (17.7) o0.001
Vitality 70.4 (23.8) 60.4 (24.3) 69.9 (24.1) 63.5 (21.3) 57.8 (23.6) 54.8 (22.7) o0.001
Social Functioning 88.0 (20.5) 84.5 (20.8) 81.8 (23.1) 86.7 (19.7) 83.4 (23.5) 84.6 (21.7) 0.64
Role emotional 91.0 (27.6) 74.7 (40.0) 81.0 (36.9) 85.5 (32.5) 81.9 (35.2) 90 (26.5) 0.21
Mental health 82.2 (14.8) 71.2 (21.4) 77.6 (21.9) 77.3 (21.7) 75.0 (22.1) 75.5 (19.1) 0.42
SGRQ
Symptoms 22.3 (15.4) 30.8 (21.7) 35.9 (20.6) 39.8 (19.7) 45 (20.9) 50.4 (19.0) o0.001
Activity 33.2 (18.1) 44.1 (24.8) 45.9 (21.6) 50.5 (19.9) 55.5 (29.1) 66.6 (20.8) o0.001
Impact 15.3 (14.8) 22.1 (19.6) 28.1 (18.2) 28.7 (19.3) 35.2 (18.2) 43.1 (18.2) o0.001
Total 22.4 (14.2) 30.2 (19.7) 34.8 (17.8) 37.1 (17.6) 43 (16.9) 51.5 (16.5) o0.001
ICS: inhaled corticosteroids. FEV1%: % FEV1 of predicted value.
ANOVA test for all analisys, except dyspnea, GOLD stages and previous hospitalizations where Chi-square test was used.
Dyspnea, GOLD stages and previous hospitalizations in frequencies and, in parenthesis, percentages. For all other variables,
means and, in parenthesis, standard deviations.
aPatients with two medications were divided according to their use of inhaled corticosteroids.
COPD medication and quality of life 491were somewhat different from those who had been
prescribed two bronchodilators—they smoked less,
had higher FEV1%, and had been hospitalized on
fewer occasions than those who took two bronch-
odilators. With respect to the dyspnea level,
patients with two medicines (one of which was an
ICS) had a lower level of dyspnea than those with
two bronchodilators. Nevertheless, with regard to
HRQL measured according to the SGRQ, patients
who used ICS showed a higher quality of life in
three areas although these did not reach significant
values. There were no statistically significant
differences in the SF-36.After adjustment by confounding variables, as
severity of the disease and comorbidities, by
multiple regression models (Table 5), we found a
progressive increase in the total SGRQ score with
increasing number of medications used. Scores
ranged from 3.4 to 13.2 more points, according to
whether patients took between 1 and 4 or more
medicines, respectively, than those who did not
take any medicine. On the other hand, in model 2,
patients who took ICS as a second medicine rather
than a bronchodilator had a slightly lower total
score than those who had been prescribed two
bronchodilators, once this had been adjusted
ARTICLE IN PRESS
Table 4 Characteristics and HRQL of patients with FEV1% higher than 50% ðn ¼ 304Þ.
ICS users (181) No ICS user (123) P-value
Age, yr (mean7SD) 66.6 (8.7) 65.5 (9.0) 0.31
FEV1% (mean7SD) 62.3 (9.7) 61.3 (9.0) 0.23
Dyspnea score, n (%) 0.024
1 15 (8.3) 20 (16.3)
2 94 (51.9) 72 (58.5)
3 69 (38.1) 29 (23.6)
X4 3 (1.7) 2 (1.6)
Previous visits to the ER, n (%) 0.026
0 138 (76.2) 107 (87.0)
1 26 (14.4) 13 (10.6)
X2 17 (9.4) 3 (2.4)
SF-36
Physical functioning 62.7 (21.2) 70.1 (21.3) 0.0031
Role physical 80.9 (33.4) 81.9 (34.2) 0.80
Bodily pain 67.7 (28.8) 72.0 (26.9) 0.18
General health 49.2 (23.5) 52.0 (20.8) 0.28
Vitality 59.9 (24.3) 64.3 (23.3) 0.10
Social functioning 82.7 (23.7) 87.6 (19.4) 0.056
Role emotional 80.1 (36.6) 83.2 (34.2) 0.45
Mental health 74.3 (22.4) 75.0 (21.4) 0.78
SGRQ
Symptoms 42.0 (20.3) 33.3 (19.2) 0.0002
Activity 49.6 (19.5) 43.8 (20.6) 0.013
Impacts 31.5 (17.8) 24.1 (18.2) 0.0005
Total 38.7 (16.7) 31.7 (17.3) 0.0005
FEV1%: % FEV1 of predicted value; HRQL: Health related quality of life; ER: Emergency room; ICS: Inhaled corticosteroids; SGRQ:
St. George Respiratory Questionnaire; t-Student test for all variables except for dysnea and previous visit to the ER where Chi-
Square test was used.
C. Esteban et al.492according to other variables of interest. However,
the differences were not statistically significant
between these two groups.Discussion
This study of more than 600 patients with COPD
drawn from usual clinical practice demonstrates an
association between HRQL and the number of
medicines used by patients. We also observed an
association between the level of dyspnea and FEV1%
and the number of drugs prescribed the treatment
of COPD. Although ICS were the third most
commonly used medication for the treatment of
COPD, their use was not always in accordance with
the indications established in guidelines.4
In our study, the most frequently used drugs were
b2A and AC, with a b2A/AC ratio of 1.07. Other
studies7,9,20 have observed lower use of AC. In
studies of a similar design, such as that by Roche et
al.20 AC was used in 56% of cases and methyl-xanthines in 31%. In a study by Miravitlles et al.21
these medications are used in 87.5% and 41% of
cases, respectively. In our series, 86.4% of patients
used AC and 14% used methylxanthines. We should
point out that the characteristics of the cohorts are
different, as the severity of patients according to
FEV1% varies from 58.2%
20 to 35.9%.21 It must also
be noted that the study by Miravitlles included only
patients in stages II and III of the ATS classification.
Although our population showed an average FEV1%
of 49.7%, it covered a broad severity spectrum of
this illness. Analyzing only patients in stages II and
III of the ATS in our series, AC were used by 90.3%
and 96%, respectively, while methylxanthines were
used by 17.5% and 33.7%. Therefore, our patients
used more AC and fewer methylxanthines than
patients included in other studies.20,21
There is a clear increase in the number of
medications used as the dyspnea level rises. In
the same way, the decrease in FEV1% is linked to an
increase in the number of medications used.
On the other hand, a deterioration in HRQL can
be seen as the number of medications prescribed
ARTICLE IN PRESS
Table 5 Association of prescribed drugs with total SGRQ score adjusted by clinical and functional
characteristics.
Model 1 Model 2
B-coefficient (SE) P-value B-coefficient (SE) P-value
Constant 34.11 (4.51) o 0.0001 34.65 (4.51) o 0.0001
Age 0.43 (0.06) o 0.0001 0.42 (0.07) o 0.0001
FEV1% 0.18 (0.04) o 0.0001 0.20 (0.04) o 0.0001
Dyspnea score
1
2 12.04 (2.38) o 0.0001 12.11(2.39) o 0.0001
3 23.66 (2.52) o 0.0001 23.84 (2.53) o 0.0001
X4 32.92 (3.63) o 0.0001 33.53 (3.62) o 0.0001
Coexisting chronic conditions
0
1 0.94 (1.64) 0.56 1.01 (1.65) 0.53
2 1.87 (1.72) 0.27 1.87 (1.72) 0.28
X3 6.26 (1.81) 0.0006 6.07 (1.80) 0.0008
Hospitalizations
0
1 2.41 (1.44) 0.09 2.61 (1.45) 0.07
2 9.07 (2.24) o 0.0001 9.12 (2.24) o 0.0001
X3 10.11 (2.23) o 0.0001 10.49 (2.22) o 0.0001
Number of drugs
0
1 3.36 (3.93) 0.39
2 6.54 (3.01) 0.03
3 10.31 (2.98) 0.0006
X4 13.20 (3.44) o 0.0001
Number of drugs by ICS
0
1 3.28 (3.94) 0.40
2 (no ICS) 6.02 (3.09) 0.05
2 (with ICS) 7.21 (3.52) 0.04
X3 10.51 (2.98) 0.0005
ICS: Inhaled corticosteroids.
Model 1 includes as dependent variables the total SGRQ score and as independent variable the number of medicines.
Model 2 includes as dependent variables the total SGRQ score and as independent variable the number of medicines making a
differentiation between those who took ICS as the second prescribed medicine, and those who did not.
In both models, the comparison group was made up of patients who did not take any medication. Both models were adjusted for
variables such as age, FEV1, dyspnea, main comorbidities and the number of previous hospitalizations.
COPD medication and quality of life 493increases. These results are similar to those
described in a study by Miravitlles et al.21 This is
demonstrated especially for all areas of the SGRQ.
In the SF-36, differences are found in PF. In the
multivariate analysis, patients who took two
medications scored 6.54 points more in the total
SGRQ score than patients who did not take any
medications at all, exceeding a score of 4 points,
which would be considered clinically significant.18
In other studies with similar characteristics to
our sample, ICS were used by 76%20 and 64.9%21 of
all patients. These figures are similar to thosedescribed in other studies,6 although these corre-
spond to clinical trials. In view of this, the cohorts
analyzed in the aforementioned studies may differ
significantly from the patients in our study and from
those included in other studies in which the
patients came from respiratory outpatient clinics.
In our series, ICS were used by 66% of patients and
represented the third most frequently used drug.
The use of ICS increases in accordance with the
severity of COPD, defined in accordance with the
dyspnea and FEV1% levels, and they are prescribed
after b2A and AC.
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scribed to patients with an FEV1% o50% and
frequent exacerbations of COPD.4 In accordance
with this guideline, 59% of patients in our study
with an FEV1%450% should not be taking ICS (Table
4). Nevertheless, the fact that this previous group
of patients presents a number of significantly
different worse characteristics than patients
with an FEV1% 450% and who do not use ICS, with
respect to the dyspnea level, the number of
previous assessments by the emergency services
and HRQL, is especially noteworthy. With regard to
HRQL, patients who received ICS had a worse HRQL
and the statistically significant differences be-
tween both groups were in the PF of the SF-36
and in all areas of the SGRQ. The differences in all
the areas of the SGRQ were greater than 4 points
between both groups. To sum up, apparently there
are differences in the levels of severity between
both groups which may justify the use of ICS in
some patients with an FEV1% 450%, especially
when the cut off point to establish their prescrip-
tion in an FEV1% at 50% is somewhat arbitrary.
Moreover, it is well known that ICS reduce the
frequency of exacerbations and reduce the fall in
HRQL,22 and that the HRQL is already impaired
during the first stages of the illness.23 On the other
hand, recent publications suggest that the use of
ICS may reduce mortality and hospitalization rates
in these patients.24 All such findings should lead to
a clearer definition for the use of ICS in COPD.
The 42 patients for whom the second medicine
prescribed was an ICS instead of a bronchodilator
are especially interesting. In view of the design of
our study and the small sample size, we cannot
establish which factors determine the introduction
of ICS as a second medicine. The tendency
detected in this group of patients is that they are
younger, have a higher FEV1% and a better HRQL,
although the differences are not statistically
significant. It might be thought that these were
asthma patients because they were prescribed as
second medicine an ICS. However, we designed
strict inclusion criteria to prevent asthma patients
from being included in the study. Even those who
might have been considered as suffering from COPD
and asthma were excluded. Nevertheless, these
patients may have had higher bronchial hyperreac-
tivity, and this circumstance was not evaluated in-
depth in our study.
The most important limitation of our study was
its cross-sectional design, which meant it was
impossible to establish causation or conclude that
the worst HRQL determines the use of more
medications, or that the worst HRQL in the group
of patients with an FEV1% 450% determines thatthey should be treated with ICS. The hypotheses
proposed by Miravitlles et al.,21 i.e., that the use of
an increasing number of medicines lowers HRQL,
may be correct. However, in our patients this
possibility does not seem likely given the fact that
those who used more medicines presented with
more severe symptoms not only with regard to the
dyspnea level and FEV1% but had also received
more previous assessments in the hospital emer-
gency services. Our sample includes almost exclu-
sively men, which just reflects the real distribution
of our COPD patients in this country where women
begun to smoke late in the 20th century, this has
been seen in others Spanish studies.23,25 Never-
theless, this fact limits the generability of our
results.
In conclusion, this study demonstrates an asso-
ciation between number of medications prescribed
to patient with COPD and their HRQL, measured by
the total SGRQ, after adjustment by the severity of
the disease. There was also an association between
dyspnea level and FEV1%, and the number of
medicines prescribed. As in the case of bronchodi-
lators, the prescription of ICS is also linked to the
dyspnea level and level of deterioration of FEV1%.
The prescription of ICS are not entirely in accor-
dance with the indications set out in guidelines.
Nevertheless, within the group of patients who
should not be prescribed ICS in accordance with the
current guidelines, there are subgroups with
peculiar characteristics that might justify their
use, based, maybe, on their dyspnea level, number
of previous assessments by the emergency services
or HRQL. Furthermore, there is another group of
patients who are prescribed ICS instead of a
bronchodilator as a second medicine, who may
have a number of peculiar characteristics that we
have not found though should be studied with
larger sample sizes. Maybe, the prescription of this
medicine is due to other circumstances, perhaps
bronchial hyperreactivity, but it will be necessary
to demonstrate this in subsequent studies.Acknowledgments
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